GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Freeline Therapeutics Holdings PLC (NAS:FRLN) » Definitions » Price-to-Owner-Earnings

Freeline Therapeutics Holdings (Freeline Therapeutics Holdings) Price-to-Owner-Earnings : (As of Jun. 07, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Freeline Therapeutics Holdings Price-to-Owner-Earnings?

As of today (2024-06-07), Freeline Therapeutics Holdings's share price is $6.48. Freeline Therapeutics Holdings does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for Freeline Therapeutics Holdings's Price-to-Owner-Earnings or its related term are showing as below:


FRLN's Price-to-Owner-Earnings is not ranked *
in the Biotechnology industry.
Industry Median: 33.745
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2024-06-07), Freeline Therapeutics Holdings's share price is $6.48. Freeline Therapeutics Holdings's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2023 was $-11.40. Therefore, Freeline Therapeutics Holdings's PE Ratio for today is At Loss.

As of today (2024-06-07), Freeline Therapeutics Holdings's share price is $6.48. Freeline Therapeutics Holdings's EPS without NRI for the trailing twelve months (TTM) ended in was $-14.88. Therefore, Freeline Therapeutics Holdings's PE Ratio without NRI for today is At Loss.


Freeline Therapeutics Holdings Price-to-Owner-Earnings Historical Data

The historical data trend for Freeline Therapeutics Holdings's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Freeline Therapeutics Holdings Price-to-Owner-Earnings Chart

Freeline Therapeutics Holdings Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22
Price-to-Owner-Earnings
- - - - -

Freeline Therapeutics Holdings Quarterly Data
Dec18 Jun19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Freeline Therapeutics Holdings's Price-to-Owner-Earnings

For the Biotechnology subindustry, Freeline Therapeutics Holdings's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Freeline Therapeutics Holdings's Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Freeline Therapeutics Holdings's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Freeline Therapeutics Holdings's Price-to-Owner-Earnings falls into.



Freeline Therapeutics Holdings Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Freeline Therapeutics Holdings's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=6.48/0.00
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Freeline Therapeutics Holdings  (NAS:FRLN) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Freeline Therapeutics Holdings Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Freeline Therapeutics Holdings's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Freeline Therapeutics Holdings (Freeline Therapeutics Holdings) Business Description

Traded in Other Exchanges
N/A
Address
Gunnels Wood Road, Sycamore House, Stevenage, Hertfordshire, GBR, SG1 2BP
Freeline Therapeutics Holdings PLC is a clinical-stage biotechnology company developing transformative adeno-associated virus (AAV) vector-mediated gene therapies for patients suffering from inherited systemic debilitating diseases. Its lead product candidates are FLT180a for the treatment of hemophilia B, FLT190 for the treatment of Fabry disease and FLT201 for the treatment of Gaucher disease Type 1.

Freeline Therapeutics Holdings (Freeline Therapeutics Holdings) Headlines

From GuruFocus

Freeline Announces Proposed ADS Ratio Change

By sperokesalga sperokesalga 04-21-2023

Freeline Reports January 2023 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

By Stock market mentor Stock market mentor 02-02-2023